|
Research – Clinical Trials
Pediatric ID receives Federal funding through the National
Institutes of Health to participate in multi-centered clinical trials whose
primary goal is to find the optimal treatment for children infected and
affected by HIV.
International Maternal Pediatric Adolescent AIDS Clinical
Trials (IMPAACT) Group
http://pactg.s-3.com
BLHC Pediatric ID, under the leadership of the Principal
Investigator Murli Purswani MD, was recently awarded over $1.2 million to
participate as a Clinical Trials Unit and a Clinical Research Site in the
IMPAACT Group. The mission of the IMPAACT group, which is worldwide in
scope, will be to significantly decrease the mortality and morbidity
associated with HIV disease in pregnant women, children, and adolescents by:
 |
Developing and evaluating safe and cost effective
approaches for the interruption of mother-to-infant transmission
|
|
Evaluating treatments for HIV-infected children,
adolescents, and pregnant women, including treatment and prevention of
co-infections and co-morbidities |
|
Evaluating vaccines for the prevention of HIV sexual
transmission among adolescents |
Pediatric HIV/AIDS Cohort Study (PHACS)
http://phacs.nichdclinicalstudies.org/default.asp
BLHC Pediatric ID, under the leadership of the Principal
Investigator Murli Purswani MD, was recently awarded over $300,000 to
participate as a Clinical Trials Unit in the PHACS Group. The goal of PHACS
is to address outstanding critical research questions on the consequences of
fetal and neonatal exposure to antiretroviral chemotherapy in a
representative cohort of HIV-exposed, uninfected children in the United
States and the clinical course of perinatally-acquired HIV infection in
pre-adolescents and adolescents.
Pediatric ID also participates in Pharmaceutical Industry
Sponsored Clinical Trials.
MedImmune Sponsored PREEMIE Study
BLHC is currently participating in the first year of a
two-year pharmacoeconomic study to find out how many premature infants, less
than 6 months of age and who are not recommended by the American Academy of
Pediatrics to receive palivizumab (a medication used to prevent RSV in
premature babies), are hospitalized or seek medical attention for RSV lower
respiratory tract illness. |
BRONX-LEBANON HOSPITAL CENTER
